Severe cytomegalovirus disease with encephalitis after CAR‐T cell therapy: A rare but potentially fatal complication. Issue 11 (14th August 2021)

• Record Type: Journal Article
• Authors: Cousin, Elie; Belicard, Félicie; Michel, Laure; Pronier, Charlotte; Lassalle, Nicolas; Lamy, Thierry; Houot, Roch; Lhomme, Faustine
• Is Part Of: Journal of medical virology. Volume 93:Issue 11(2021)
• Page Start: 6398
• Page End: 6403
• Publication Date: 2021-08-14
• Subjects: CAR‐T cells therapy -- CMV encephalopathy -- immunosupressions; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27257
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Cytomegalovirus (CMV) is a ubiquitous herpes virus that develops lifelong latency following primary infection and can be reactivated following immune suppression. CMV encephalopathy has been described in few reports after hematopoietic stem cell transplantation and in patients with acquired immunodeficiency syndrome. To the best of our knowledge, CMV encephalopathy following CAR‐T cells infusion had not been previously reported. Initial CMV viral load and monitoring are crucial in patients with CAR‐T cells to allow early intervention with aggressive antiviral treatment without delay if needed.